NOVC.DE - NOVO-NORDISK NAM.B DK-,20
| Previous Close | 42.77 |
| Open | 42.81 |
| Bid | 42.98 x N/A |
| Ask | 43.25 x N/A |
| Day's Range | 42.81 - 43.26 |
| 52 Week Range | 35.75 - 46.83 |
| Volume | 15,799 |
| Avg. Volume | 12,442 |
| Market Cap | N/A |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Bloomberg•5 months ago
Novo Nordisk CEO Applauds Trump Plan to Limit Rebates
Feb.01 -- Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, the world's biggest maker of diabetes drugs, discusses earnings, the company's growth potential, pricing and a proposal by the administration of U.S. President Donald Trump to limit the discounts pharma companies pay middlemen that have been criticized for driving up costs for patients. Jorgensen speaks on "Bloomberg Markets: European Open."
- Motley Fool•23 days ago
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
- Benzinga•last month
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
- Investor's Business Daily•last month
Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out
Shares of pharmaceutical companies Johnson & Johnson and Novo Nordisk popped Wednesday on bullish expectations for their diabetes treatments after the American Diabetes Association meeting.
- Investor's Business Daily•last month
This Pharma Wants To Scoop Its Rivals With An Oral Diabetes Med
Pharmaceutical company Novo Nordisk said Tuesday its experimental diabetes treatment proved safe in patients with heart disease. It could rival drugs from Lilly, AstraZeneca and Sanofi.
- Reuters•last month
CORRECTED-Oral Novo Nordisk diabetes drug poses no more heart risk than placebo -study
An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday. Patients with type 2 diabetics and either heart disease or at high risk for heart problems who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8% compared with 4.8% for placebo, successfully demonstrating non-inferiortiy.
- Reuters•last month
UPDATE 2-China stimulus, German rally help European stock end higher
European stocks finished higher for a third day on Tuesday, as German shares caught up with a global stock rally after a holiday on easing trade tensions, while fresh stimulus for China's slowing economy boosted the basic resources sector. The pan-European STOXX 600 index closed at its highest level since May 17, with miners, auto stocks and chemical companies tacking on biggest gains after reports that Beijing was opening the door to more spending by local governments.
- Barrons.com•last month
Eli Lilly Stock Is Falling and Novo Nordisk Is Rising on Diabetes-Drug Results
Eli Lilly announced positive results in a long-term trial of its diabetes drug Trulicity, but that doesn’t seem to have been enough for Wall Street.
- Motley Fool•2 months ago
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug
Oral semaglutide is on its way.
Motley Fool•2 months agoNovo Nordisk A/S (NVO) Q1 2019 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2019.
Motley Fool•3 months agoStrongbridge Biopharma (SBBP) Q1 2019 Earnings Call Transcript
SBBP earnings call for the period ending March 31, 2019.
Motley Fool•3 months agoStrongbridge Biopharma plc (SBBP) Q1 2019 Earnings Call Transcript
SBBP earnings call for the period ending March 31, 2019
- Motley Fool•3 months ago
2 Reasons Gilead Sciences' NASH Program Could Bounce Back
It's been a rough few years, but an unexpected partnership could put the biotech's liver disease program back on top.
- TheStreet.com•3 months ago
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
in their efforts to help combat liver disease. The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH). "The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
- Reuters•3 months ago
Novo Nordisk and Gilead team up to test fatty liver disease treatment
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.
Motley Fool•5 months agoStrongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript
SBBP earnings call for the period ending December 31, 2018.
- Motley Fool•5 months ago
Novo Nordisk Is on the Upswing -- for Now
The full year may be a different story.
Motley Fool•5 months agoNovo Nordisk (NVO) Q4 2018 Earnings Conference Call Transcript
NVO earnings call for the period ending December 31, 2018.
- Reuters•5 months ago
Novo Nordisk CEO backs ending drug industry rebate system
COPENHAGEN (Reuters) - The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy ...
- Associated Press•5 months ago
Novo Nordisk: 4Q Earnings Snapshot
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 54 cents. The drugmaker posted revenue of $4.55 billion in the period. For the year, the company reported profit of ...
- Reuters•5 months ago
Novo Nordisk's new diabetes drug, outlook lift shares
Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares. The world's top maker of diabetes drugs expects 2019 sales growth of 2-5 percent and operating profit growth of 2-6 percent, both measured in local currency. Novo faces pressure on prices from competitors and lawmakers in the United States and is pinning its growth hopes on a once-weekly injection and tablet version of its GLP-1 drug semaglutide for diabetes, as well as anti-obesity treatments.
